Peptides for the Immune System: LL-37 and KPV in Research

EXOMA Scientific Team · Publicado el 13 de abril de 2026 · Actualizado el 18 de agosto de 2026

Analysis of the antimicrobial peptides LL-37 and the anti-inflammatory KPV. Innate defense mechanisms, immune modulation and preclinical evidence.

Host Defense Peptides

Antimicrobial peptides (AMPs) and immunomodulatory peptides represent an active frontier in immunological research. LL-37 y KPV are two compounds that have generated significant interest for their complementary mechanisms of action on the immune system.

LL-37: The Human Antimicrobial Peptide

Origin and Structure

LL-37 is the only member of the cathelicidin family in humans:

• Full name: Human Cathelicidin Antimicrobial Peptide (hCAP18/LL-37)
• Structure: Amphipathic α-helical peptide of 37 amino acids
• Sequence: Begins with two leucines (LL-), hence its name
• Gene: CAMP (chromosome 3p21)
• Expression: Neutrophils, macrophages, epithelial cells, keratinocytes

Antimicrobial Mechanisms

LL-37 exerts broad-spectrum antimicrobial activity through:

1. Membrane disruption: Se inserta en la membrana bacteriana creando poros
2. Carpet model: A concentraciones altas, cubre la superficie bacteriana como una alfombra, desintegrando la membrana
3. LPS neutralization: Se une al lipopolisacárido bacteriano, previniendo la activación de TLR4
4. Biofilm inhibition: Prevents the formation of and disperses existing biofilms of P. aeruginosa and S. aureus

Immunomodulatory Functions

Beyond its direct antimicrobial activity, LL-37 modulates the immune response:

• Chemotaxis: Recruits neutrophils, monocytes, and T lymphocytes to the site of infection
• Receptor activation: Signals through FPR2/ALX (formyl peptide receptor)
• Cytokine regulation: Modulates the production of IL-1β, IL-6, IL-8, and TNF-α
• Promotion of angiogenesis: Stimulates VEGF in endothelial cells
• Tissue repair: Promotes the migration of keratinocytes and fibroblasts

Spectrum of Activity

Scientific Evidence

• Wound healing: Studies in Journal of Investigative Dermatology demonstrate acceleration of skin repair
• Resistant infections: Activity against MRSA and multidrug-resistant bacteria
• Sepsis: Neutralization of endotoxins in preclinical models
• Dermatology: Role in the pathogenesis of rosacea (elevated levels) and psoriasis

KPV: The Anti-inflammatory Tripeptide

Origin and Structure

KPV is a tripeptide derived from α-MSH:

• Sequence: Lys-Pro-Val (amino acids 11-13 of α-MSH)
• Molecular weight: 342 Da
• Origin: C-terminal fragment of alpha-melanocyte-stimulating hormone
• Discovery: Identified as the minimal fragment with anti-inflammatory activity of α-MSH

Mechanism of Action

KPV exerts its anti-inflammatory effects through:

1. NF-κB inhibition: Blocks the nuclear translocation of the pro-inflammatory transcription factor
2. Direct nuclear penetration: Unlike other peptides, KPV can enter the cell nucleus
3. Modulation of MAP kinases: Reduce la fosforilación de p38 y JNK
4. Inflammasome regulation: Decreases NLRP3 activation

Research in Intestinal Inflammation

KPV has shown promising results in models of inflammatory bowel disease (IBD):

• Reduction of pro-inflammatory cytokines: IL-1β, IL-6, TNF-α
• Preservation of the intestinal barrier: Maintenance of tight junctions
• Microbiota modulation: Indirect effects on the microbial composition
• Oral administration: Stability in the gastric environment for research

Other Research Areas

• Dermatology: Cutaneous anti-inflammatory properties
• Neurology: Neuroprotective potential via inhibition of neuroinflammation
• Arthritis: Reduction of joint inflammation in animal models
• Allergy: Modulation of the mast cell response

LL-37 vs KPV comparison

LL-37 + KPV synergy

The combination of these two peptides offers a dual approach:

• LL-37: Eliminates pathogens and recruits immune cells
• KPV: Controls the inflammatory response to prevent tissue damage

This combination replicates the physiological immune response: active defense with controlled resolution of inflammation.

Future Perspectives

Research on immunological peptides is expanding toward:

• Sustained-release formulations
• Combinations with conventional antibiotics
• Applications in chronic wounds and biofilm infections
• Development of more stable and potent analogs

Conclusion

LL-37 and KPV represent two complementary approaches to the modulation of the immune system. LL-37 provides direct antimicrobial defense and immune activation, whereas KPV offers precise anti-inflammatory control. Their combined study opens possibilities in the research of balanced immune responses.

Both compounds are available at Exoma Peptides with a certified COA.

References

Material for research use only. Verified primary sources supporting the scientific claims of this article:

1. Dürr UHN, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta. 2006;1758(9):1408-1425. doi:10.1016/j.bbamem.2006.03.030. PMID 16716248. (review)
2. Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J. 1989;3(11):2282-2284. doi:10.1096/fasebj.3.11.2550304. PMID 2550304. (animal)
3. Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003;306(2):631-637. doi:10.1124/jpet.103.051623. PMID 12750433. (animal)
4. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. doi:10.1002/ibd.20334. PMID 18092346. (animal)
5. Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. doi:10.1053/j.gastro.2007.10.026. PMID 18061177. (in vitro and animal)

Products available at EXOMA

• LL-37